Cargando…
The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
Pulmonary arterial hypertension (PAH) is an aggressive vascular remodeling disease that carries a high morbidity and mortality rate. Treprostinil (Remodulin) is a stable prostacyclin analogue with potent vasodilatory and anti-proliferative activity, approved by the FDA and WHO as a treatment for PAH...
Autores principales: | Cunningham, Kevin P., Clapp, Lucie H., Mathie, Alistair, Veale, Emma L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276018/ https://www.ncbi.nlm.nih.gov/pubmed/34267666 http://dx.doi.org/10.3389/fphar.2021.705421 |
Ejemplares similares
-
Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine and CEN-092
por: Walsh, Yvonne, et al.
Publicado: (2021) -
Convergence of Multiple Stimuli to a Single Gate in TREK1 and TRAAK Potassium Channels
por: Choveau, Frank S, et al.
Publicado: (2021) -
Pharmacologically reversible, loss of function mutations in the TM2 and TM4 inner pore helices of TREK-1 K2P channels
por: Al-Moubarak, Ehab, et al.
Publicado: (2019) -
Activation of TREK-1, but Not TREK-2, Channel by Mood Stabilizers
por: Kim, Eun-Jin, et al.
Publicado: (2017) -
Corrigendum: Convergence of Multiple Stimuli to a Single Gate in TREK1 and TRAAK Potassium Channels
por: Choveau, Frank S., et al.
Publicado: (2021)